Neuropathix, Inc. (“Neuropathix”) is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of patented new molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
Neuropathix’ subsidiary Kannalife Sciences is the only company to be granted an exclusive license from National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by Sports Illustrated as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.”
The Neuropathix family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. The Company conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
We are involved in the research and development of novel therapeutics to break the blood/brain barrier to be used for the treatment and prevention of oxidative and neuro-toxic stresses born from a variety of ailments and illnesses.
Our scientific team, comprised of dedicated professionals, clinicians and bio-chemists, all have a strong background in phyto-medical, biological and pharmaceutical sciences with a long track record of successfully developing drugs from plant sources that are complex in nature and structure. The team collectively has over 75+ years of research and pharmaceutical experience and have been published in over 300 notable journal publications and hold inventorships in over 65 patents.
Our goal is to become a profitable company with socially responsible practices that develop treatments and seeks to improve the quality of life of patients with oxidative stress and neurodegenerative diseases.
